Loading...
•
Jun 30, 2022
Vistagen Q1 2023 Earnings Report
Reported financial results for the first quarter of fiscal year 2023 and provided a corporate update.
Key Takeaways
VistaGen Therapeutics reported its financial results for the first quarter of fiscal year 2023 ended June 30, 2022. The company is evaluating the results of PALISADE-1 and conducting an interim analysis of PALISADE-2. They anticipate a considerable reduction in external spending to conserve cash.
PH94B did not achieve its primary efficacy endpoint during PALISADE-1.
Enrollment in PALISADE-2 has been paused while an interim analysis of available data is conducted.
Preliminary data from the PALISADE open label safety study suggest cumulative functional improvement with PH94B use.
The company anticipates submission of its PH10 IND in MDD in 2022 and initiation of a small U.S. Phase 1 study in 2022 to facilitate potential Phase 2B development of PH10 as a rapid-onset, stand-alone treatment of MDD in 2023.
Vistagen
Vistagen
Forward Guidance
VistaGen anticipates a considerable reduction in external spending to conserve cash and extend the Company’s cash runway covering at least the next 12 months.